Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC

Summary

The purpose of this study is to assess the 2-month progression-free survival in patients with advanced or metastatic, non-squamous cell lung cancer treated with weekly low dose docetaxel in combination with a biologic dose of sorafenib.

Timeline

Start

2008-01

Primary completion

2009-10

Completion

2011-03

Outcome

Outcome not reported

Stopped (Business): “Sponsors withdrew funding; preliminary efficacy data was not encouraging.”

Drugs

Indications